State of the art: MDS

preview_player
Показать описание
David Steensma, MD, Dana-Farber Cancer Institute, Boston, MA, discusses current treatment options for both high and low-risk myelodysplastic syndromes (MDS) patients. Dr Steensma reveals that there’s not a well-established second-line therapy, representing an unmet clinical need. This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.
Рекомендации по теме